Perfusion MRI After Donepezil in Lewy Body Dementia

描述（由申请人提供）： 痴呆症有效治疗的一个主要限制是对神经元传递和行为之间关系的理解不足。本研究将使用动脉自旋标记灌注MRI（ASL-pMRI）测量弥漫性路易体痴呆患者急性和慢性给予胆碱酯酶抑制剂（ChEI）后局部脑血流量（rCBF）的变化。将同时获得高分辨率结构成像和当代神经心理学评估。由此可以定义认知性能和rCBF变化之间的关系。此外，结合结构和灌注MRI将提供可能预测ChEI临床反应的信息。该试验将包括两个阶段，第一阶段是双盲、随机、交叉、安慰剂对照试验，以测量单次口服ChEI对认知功能和rCBF的影响。第二阶段将是一项开放标签的前瞻性研究，以评估在三个月内给予ChEI的慢性效应。

DESCRIPTION (provided by applicant): A major limitation in the development of effective treatment for dementia has been poor understanding of the relationship between neuronal transmission and behavior. This study will use arterial spin labeled perfusion MRI (ASL-pMRI) to measure changes in regional cerebral blood flow (rCBF) following acute and chronic administration of cholinesterase inhibitors (ChEI) in diffuse Lewy body dementia. Simultaneous high resolution structural imaging and contemporary neuropsychological assessments will be obtained. From this a relationship between cognitive performance and changes in rCBF can be defined. Additionally, combined structural and perfusion MRI will provide information that may predict clinical response to ChEI. The trial will include two phases, first, a double-blind, randomized, crossover, placebo-controlled trial to measure the effects of a single oral dose of ChEI on cognitive function and rCBF. The second phase will be an open labeled, prospective study to assess the chronic effects of ChEI administered over a period of three months.